Literature DB >> 26800563

Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.

Reut Shnerb Ganor1, Dror Harats1, Ginette Schiby1, David Gailani1, Hanna Levkovitz1, Camila Avivi1, Ilia Tamarin1, Aviv Shaish1, Ophira Salomon2.   

Abstract

OBJECTIVE: Atherosclerosis and atherothrombosis are still major causes of mortality in the Western world, even after the widespread use of cholesterol-lowering medications. Recently, an association between local thrombin generation and atherosclerotic burden has been reported. Here, we studied the role of factor XI (FXI) deficiency in the process of atherosclerosis in mice. APPROACH AND
RESULTS: Apolipoprotein E/FXI double knockout mice, created for the first time in our laboratory. There was no difference in cholesterol levels or lipoprotein profiles between apolipoprotein E knockout and double knockout mice. Nevertheless, in 24-week-old double knockout mice, the atherosclerotic lesion area in the aortic sinus was reduced by 32% (P=0.004) in comparison with apolipoprotein E knockout mice. In 42-week-old double knockout mice, FXI deficiency inhibited atherosclerosis progression significantly in the aortic sinus (25% reduction, P=0.024) and in the aortic arch (49% reduction, P=0.028), with a prominent reduction of macrophage infiltration in the atherosclerotic lesions.
CONCLUSIONS: FXI deprivation was shown to slow down atherogenesis in mice. The results suggest that the development of atherosclerosis can be prevented by targeting FXI.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  atherosclerosis; factor XI

Mesh:

Substances:

Year:  2016        PMID: 26800563      PMCID: PMC4785893          DOI: 10.1161/ATVBAHA.115.306954

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Lawrence L Johnson; Erik I Tucker; Andras Gruber; David Gailani; Stephen T Smiley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

Review 2.  The hemostatic system as a modulator of atherosclerosis.

Authors:  Julian Ilcheff Borissoff; Henri M H Spronk; Hugo ten Cate
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

3.  Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.

Authors:  David T Yang; Michele M Flanders; Hyunhee Kim; George M Rodgers
Journal:  Am J Clin Pathol       Date:  2006-09       Impact factor: 2.493

4.  Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice.

Authors:  Florian Bea; Joerg Kreuzer; Michael Preusch; Sandra Schaab; Berend Isermann; Michael E Rosenfeld; Hugo Katus; Erwin Blessing
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-21       Impact factor: 8.311

5.  Novel insights into the development of atherosclerosis in hemophilia A mouse models.

Authors:  D R Fabri; E V de Paula; D S P Costa; J M Annichino-Bizzacchi; V R Arruda
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

6.  Does hemophilia protect against atherosclerosis? A case-control study.

Authors:  Franca Bilora; Ezio Zanon; Francesco Petrobelli; Monica Cavraro; Paolo Prandoni; Antonio Pagnan; Antonio Girolami
Journal:  Clin Appl Thromb Hemost       Date:  2006-04       Impact factor: 2.389

7.  Early atherosclerosis exhibits an enhanced procoagulant state.

Authors:  Julian Ilcheff Borissoff; Sylvia Heeneman; Evren Kilinç; Peter Kassák; René Van Oerle; Kristien Winckers; José W P Govers-Riemslag; Karly Hamulyák; Tilman M Hackeng; Mat J A P Daemen; Hugo ten Cate; Henri M H Spronk
Journal:  Circulation       Date:  2010-08-09       Impact factor: 29.690

8.  Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis.

Authors:  Erik I Tucker; David Gailani; Sawan Hurst; Qiufang Cheng; Stephen R Hanson; András Gruber
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

9.  Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.

Authors:  Ophira Salomon; David M Steinberg; Nira Koren-Morag; David Tanne; Uri Seligsohn
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

Review 10.  Mouse models for atherosclerosis and pharmaceutical modifiers.

Authors:  Susanne Zadelaar; Robert Kleemann; Lars Verschuren; Jitske de Vries-Van der Weij; José van der Hoorn; Hans M Princen; Teake Kooistra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-31       Impact factor: 8.311

View more
  14 in total

1.  Proteases, Protease-Activated Receptors, and Atherosclerosis.

Authors:  Wolfram Ruf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-06       Impact factor: 8.311

2.  Factor XI contributes to myocardial ischemia-reperfusion injury in mice.

Authors:  Christina U Lorentz; Norah G Verbout; Zhiping Cao; Lijuan Liu; Monica T Hinds; Owen J T McCarty; Ivan Ivanov; Erik I Tucker; David Gailani; András Gruber
Journal:  Blood Adv       Date:  2018-01-23

Review 3.  Factor XI as a Therapeutic Target.

Authors:  David Gailani; Andras Gruber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-12       Impact factor: 8.311

Review 4.  Fibrinogen and Fibrin in Hemostasis and Thrombosis.

Authors:  Sravya Kattula; James R Byrnes; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03       Impact factor: 8.311

5.  Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

Authors:  R H Olie; P E J van der Meijden; H M H Spronk; H Ten Cate
Journal:  Handb Exp Pharmacol       Date:  2022

6.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

7.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

Review 8.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

9.  Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Anh T P Ngo; Kelley R Jordan; Paul A Mueller; Matthew W Hagen; Stéphanie E Reitsma; Cristina Puy; Alexey S Revenko; Christina U Lorentz; Erik I Tucker; Quifang Cheng; Monica T Hinds; Sergio Fazio; Brett P Monia; David Gailani; András Gruber; Hagai Tavori; Owen J T McCarty
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

10.  A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Authors:  Bassem M Mohammed; Qiufang Cheng; Anton Matafonov; Ingrid M Verhamme; Jonas Emsley; Keith R McCrae; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.